Cargando…

The not so small role of adjuvant chemotherapy in resected non-small cell lung cancer

Detalles Bibliográficos
Autores principales:	Almquist, Daniel R., Savvides, Panayiotis, Ernani, Vinicius
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Pneumologia e Tisiologia 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8332728/ https://www.ncbi.nlm.nih.gov/pubmed/34259787 http://dx.doi.org/10.36416/1806-3756/e20210230

Ejemplares similares

Adjuvant chemotherapy of non-small-cell lung cancer
por: Douillard, J.Y.
Publicado: (2013)

Adjuvant Chemotherapy of Non-Small Cell Lung Cancer
por: Pirker, Robert
Publicado: (2012)

Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research
por: Bonomi, Maria, et al.
Publicado: (2011)

Adjuvant TKI therapy in resected EGFR-mutant non-small-cell lung cancer—ready for prime time?
por: Arulananda, Surein, et al.
Publicado: (2020)

Role of adjuvant radiotherapy in completely resected non-small-cell lung cancer
por: Péchoux, Cecile Le, et al.
Publicado: (2013)

Adjuvant chemotherapy for locally advanced non-small cell lung cancer: still state of the art or an outdated therapy?
por: Schlachtenberger, Georg, et al.
Publicado: (2023)

Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
por: Patel, Shruti R., et al.
Publicado: (2023)

Impact of age on adjuvant chemotherapy after radical resection in patients with non–small cell lung cancer
por: Zhai, Xiaoyu, et al.
Publicado: (2016)

Resectable non-small cell lung cancer: an evolving landscape
por: Loh, Jerold, et al.
Publicado: (2022)

Adjuvant Chemotherapy for Early Stage Non-Small Cell Lung Cancer
por: Patel, Manali I., et al.
Publicado: (2011)

Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold!
por: Fiorelli, Alfonso, et al.
Publicado: (2020)

Optimizing adjuvant therapy in EGFR-mutated non-small cell lung cancer
por: Shepherd, Annemarie F., et al.
Publicado: (2020)

Operable non-small cell lung cancer: induction therapy, adjuvant therapy, or both?
por: Agrafiotis, Apostolos C., et al.
Publicado: (2023)

Randomised study of adjuvant chemotherapy for completely resected p-stage I–IIIA non-small cell lung cancer
por: Nakagawa, K, et al.
Publicado: (2006)

Neoadjuvant immunotherapy in resectable non-small cell lung cancer at a checkpoint
por: Faltermeier, Claire M., et al.
Publicado: (2021)

Effectiveness and toxicity of adjuvant chemotherapy in patients with non-small cell lung cancer
por: Harada, Guilherme, et al.
Publicado: (2021)

Adjuvant chemotherapy in pathological node-negative non-small cell lung cancer
por: Cheng, Ya-Fu, et al.
Publicado: (2023)

High LARGE1 Expression May Predict Benefit from Adjuvant Chemotherapy in Resected Non-Small-Cell Lung Cancer
por: Liu, Yu, et al.
Publicado: (2021)

Use of adjuvant chemotherapy in resected non-small cell lung cancer in real-life practice: a systematic review of literature
por: Desage, Anne-Laure, et al.
Publicado: (2021)

Adjuvant chemotherapy or immunotherapy for completely resected stage IB non-small cell lung cancer: still a grey zone?
por: Lee, Kuan-Yu, et al.
Publicado: (2023)

Neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: the more cycles, the better?
por: Ulas, Ezgi B., et al.
Publicado: (2023)

Adjuvant Chemotherapy Following Surgical Resection Improves Survival in Patients With Early Stage Small Cell Lung Cancer
por: Yao, Yuanshan, et al.
Publicado: (2019)

Circulating Tumor DNA Analyses as a Potential Marker of Recurrence and Effectiveness of Adjuvant Chemotherapy for Resected Non-Small-Cell Lung Cancer
por: Kuang, Peng-Peng, et al.
Publicado: (2021)

Oral uracil–tegafur compared with intravenous chemotherapy as adjuvant therapy for resected early‐stage non‐small cell lung cancer patients
por: Liang, Sheng‐Kai, et al.
Publicado: (2023)

Adjuvant therapies for resected limited-stage small cell lung cancer
por: Lampridis, Savvas
Publicado: (2021)

Wedge resection—finding its place in early-stage non-small cell lung cancer?
por: Hill, Morgan A., et al.
Publicado: (2023)

Efficacy of second-line chemotherapy after immunotherapy in advanced non-small cell lung cancer
por: Hirata, Tsuyoshi, et al.
Publicado: (2023)

Mediastinal radiotherapy after adjuvant chemotherapy for resected non–small cell lung cancer with N2 lymphadenopathy: A novel meta-analysis
por: Harling, Leanne, et al.
Publicado: (2020)

A phase III study of adjuvant chemotherapy in patients with completely resected, node-negative non–small cell lung cancer (JCOG 0707)
por: Kunitoh, Hideo, et al.
Publicado: (2020)

Adjuvant chemotherapy for completely resected IIA–IIIA non-small cell lung cancer: compliance to guidelines, safety and efficacy in real-life practice
por: Désage, Anne-Laure, et al.
Publicado: (2022)

Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
por: Chen, Yulong, et al.
Publicado: (2023)

The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer
por: Melosky, Barbara, et al.
Publicado: (2021)

Adjuvant immunotherapy in early-stage resectable non–small cell lung cancer: A new milestone
por: Tang, Wen-Fang, et al.
Publicado: (2023)

Role of Adjuvant Radiotherapy in Non-Small Cell Lung Cancer—A Review
por: Süveg, Krisztian, et al.
Publicado: (2022)

Neoadjuvant immunotherapy with resectable non-small cell lung cancer: recent advances and future challenges
por: Ren, Sijia, et al.
Publicado: (2020)

Phase II study of adjuvant chemotherapy with pemetrexed and cisplatin with a short hydration method for completely resected nonsquamous non‐small cell lung cancer
por: Tachihara, Motoko, et al.
Publicado: (2020)

Randomised phase 3 study of adjuvant chemotherapy with or without nadroparin in patients with completely resected non-small-cell lung cancer: the NVALT-8 study
por: Groen, Harry J. M., et al.
Publicado: (2019)

A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer
por: Tanaka, Hisashi, et al.
Publicado: (2020)

Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer
por: Van Laar, Ryan K
Publicado: (2012)

Heterogeneous prognosis and adjuvant chemotherapy in pathological stage I non-small cell lung cancer patients
por: Liu, Chia-Hsin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_nn0ipgot1omtcscsh99f0pmu40